KR101414873B1 - 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물 - Google Patents

피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물 Download PDF

Info

Publication number
KR101414873B1
KR101414873B1 KR20120070359A KR20120070359A KR101414873B1 KR 101414873 B1 KR101414873 B1 KR 101414873B1 KR 20120070359 A KR20120070359 A KR 20120070359A KR 20120070359 A KR20120070359 A KR 20120070359A KR 101414873 B1 KR101414873 B1 KR 101414873B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
hydrochlorothiazide
solvate
acid
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR20120070359A
Other languages
English (en)
Korean (ko)
Other versions
KR20140006233A (ko
Inventor
김제학
남경완
박서훈
김주원
김상엽
Original Assignee
보령제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49783403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101414873(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 보령제약 주식회사 filed Critical 보령제약 주식회사
Priority to KR20120070359A priority Critical patent/KR101414873B1/ko
Priority to EP13809531.0A priority patent/EP2868316B1/en
Priority to PE2014002474A priority patent/PE20150607A1/es
Priority to SG11201408666SA priority patent/SG11201408666SA/en
Priority to MYPI2014003524A priority patent/MY165075A/en
Priority to US14/411,871 priority patent/US9457094B2/en
Priority to ES13809531.0T priority patent/ES2654207T3/es
Priority to PCT/KR2013/003734 priority patent/WO2014003305A1/ko
Priority to CN201380040573.0A priority patent/CN104602676A/zh
Priority to IN645DEN2015 priority patent/IN2015DN00645A/en
Priority to AU2013281582A priority patent/AU2013281582B2/en
Priority to MX2014015841A priority patent/MX351521B/es
Priority to CA2877444A priority patent/CA2877444C/en
Priority to BR112014032764-5A priority patent/BR112014032764B1/pt
Priority to JP2015519998A priority patent/JP6145506B2/ja
Priority to CN201910766865.1A priority patent/CN110496122A/zh
Priority to UAA201500674A priority patent/UA111434C2/uk
Priority to RU2015102553A priority patent/RU2613900C2/ru
Publication of KR20140006233A publication Critical patent/KR20140006233A/ko
Publication of KR101414873B1 publication Critical patent/KR101414873B1/ko
Application granted granted Critical
Priority to PH12014502876A priority patent/PH12014502876A1/en
Priority to ZA2014/09508A priority patent/ZA201409508B/en
Priority to CL2014003525A priority patent/CL2014003525A1/es
Priority to CO14284187A priority patent/CO7240413A2/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR20120070359A 2012-06-28 2012-06-28 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물 Active KR101414873B1 (ko)

Priority Applications (22)

Application Number Priority Date Filing Date Title
KR20120070359A KR101414873B1 (ko) 2012-06-28 2012-06-28 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
CA2877444A CA2877444C (en) 2012-06-28 2013-04-30 Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
JP2015519998A JP6145506B2 (ja) 2012-06-28 2013-04-30 フィマサルタン及びヒドロクロロチアジドを含有する薬剤学的組成物
SG11201408666SA SG11201408666SA (en) 2012-06-28 2013-04-30 Pharmaceutical composition containing fimasartan and hydrochlorothiazide
MYPI2014003524A MY165075A (en) 2012-06-28 2013-04-30 Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
US14/411,871 US9457094B2 (en) 2012-06-28 2013-04-30 Pharmaceutical composition containing fimasartan and hydrochlorothiazide
ES13809531.0T ES2654207T3 (es) 2012-06-28 2013-04-30 Composición farmacéutica que contiene fimarsatán e hidroclorotiazida
PCT/KR2013/003734 WO2014003305A1 (ko) 2012-06-28 2013-04-30 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
CN201380040573.0A CN104602676A (zh) 2012-06-28 2013-04-30 包含非马沙坦和氢氯噻嗪的药物组合物
IN645DEN2015 IN2015DN00645A (OSRAM) 2012-06-28 2013-04-30
AU2013281582A AU2013281582B2 (en) 2012-06-28 2013-04-30 Pharmaceutical composition containing fimasartan and hydrochlorothiazide
MX2014015841A MX351521B (es) 2012-06-28 2013-04-30 Composición farmacéutica que comprende fimasartan e hidroclorotiazida.
EP13809531.0A EP2868316B1 (en) 2012-06-28 2013-04-30 Pharmaceutical composition containing fimasartan and hydrochlorothiazide
BR112014032764-5A BR112014032764B1 (pt) 2012-06-28 2013-04-30 Composição farmacêutica contendo fimasartana e hidroclorotiazida, método para preparação de uma composição farmacêutica e uso de fimasartana e hidroclorotiazida
PE2014002474A PE20150607A1 (es) 2012-06-28 2013-04-30 Composicion farmaceutica que comprende fimasartan e hidroclorotiazida
CN201910766865.1A CN110496122A (zh) 2012-06-28 2013-04-30 包含非马沙坦和氢氯噻嗪的药物组合物
UAA201500674A UA111434C2 (uk) 2012-06-28 2013-04-30 Фармацевтична композиція, що містить фімасартан і гідрохлортіазид
RU2015102553A RU2613900C2 (ru) 2012-06-28 2013-04-30 Фармацевтическая композиция, содержащая фимасартан и гидрохлортиазид
PH12014502876A PH12014502876A1 (en) 2012-06-28 2014-12-23 Pharmaceutical composition containing fimasartan and hydrochlorothiazide
ZA2014/09508A ZA201409508B (en) 2012-06-28 2014-12-23 Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
CL2014003525A CL2014003525A1 (es) 2012-06-28 2014-12-24 Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CO14284187A CO7240413A2 (es) 2012-06-28 2014-12-26 Composición farmacéutica que comprende fimasartan e hidroclorotiazida

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20120070359A KR101414873B1 (ko) 2012-06-28 2012-06-28 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물

Publications (2)

Publication Number Publication Date
KR20140006233A KR20140006233A (ko) 2014-01-16
KR101414873B1 true KR101414873B1 (ko) 2014-07-03

Family

ID=49783403

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20120070359A Active KR101414873B1 (ko) 2012-06-28 2012-06-28 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물

Country Status (21)

Country Link
US (1) US9457094B2 (OSRAM)
EP (1) EP2868316B1 (OSRAM)
JP (1) JP6145506B2 (OSRAM)
KR (1) KR101414873B1 (OSRAM)
CN (2) CN104602676A (OSRAM)
AU (1) AU2013281582B2 (OSRAM)
BR (1) BR112014032764B1 (OSRAM)
CA (1) CA2877444C (OSRAM)
CL (1) CL2014003525A1 (OSRAM)
CO (1) CO7240413A2 (OSRAM)
ES (1) ES2654207T3 (OSRAM)
IN (1) IN2015DN00645A (OSRAM)
MX (1) MX351521B (OSRAM)
MY (1) MY165075A (OSRAM)
PE (1) PE20150607A1 (OSRAM)
PH (1) PH12014502876A1 (OSRAM)
RU (1) RU2613900C2 (OSRAM)
SG (1) SG11201408666SA (OSRAM)
UA (1) UA111434C2 (OSRAM)
WO (1) WO2014003305A1 (OSRAM)
ZA (1) ZA201409508B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022255760A1 (ko) * 2021-06-01 2022-12-08 주식회사 보령 고혈압을 동반한 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105395552A (zh) * 2014-09-05 2016-03-16 南京华威医药科技开发有限公司 一种含非马沙坦及其盐的固体制剂
KR101545268B1 (ko) * 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염
MX387327B (es) * 2016-01-27 2025-03-18 Boryung Pharm Composición farmacéutica para prevenir o tratar nefropatía diabética
KR102233673B1 (ko) * 2016-01-27 2021-03-30 보령제약 주식회사 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
CN105784867B (zh) * 2016-03-28 2019-01-01 北京睿创康泰医药研究院有限公司 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途
KR102201396B1 (ko) * 2017-11-30 2021-01-11 보령제약 주식회사 피마살탄을 포함하는 약학적 조성물
CN120037195B (zh) * 2023-09-28 2025-11-28 浙江百代医药科技有限公司 一种硫辛酸药物组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
HRP20040649B1 (en) * 2002-01-16 2012-12-31 Boehringer Ingelheim Pharma Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
ES2523729T3 (es) 2006-06-16 2014-12-01 Lek Pharmaceuticals D.D. Composición farmacéutica que comprende hidroclorotiazida y telmisartán
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
TR201004754A1 (tr) * 2010-06-11 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Yeni Farmasötik Kombinasyonlar
CN102397278A (zh) * 2010-09-19 2012-04-04 鲁南制药集团股份有限公司 一种抗高血压药物组合物
CN102485228B (zh) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
CN102485227B (zh) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
CN102058602B (zh) * 2010-12-21 2013-04-10 中国药科大学 一种稳定的含氯沙坦钾和氢氯噻嗪的口服固体制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
논문1:JOURNAL OF CARDIOVASCULAR PHARMACOLOGY *
논문1:JOURNAL OF CARDIOVASCULAR PHARMACOLOGY*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022255760A1 (ko) * 2021-06-01 2022-12-08 주식회사 보령 고혈압을 동반한 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
BR112014032764B1 (pt) 2021-12-07
US9457094B2 (en) 2016-10-04
US20150147394A1 (en) 2015-05-28
RU2613900C2 (ru) 2017-03-21
IN2015DN00645A (OSRAM) 2015-06-26
UA111434C2 (uk) 2016-04-25
MX2014015841A (es) 2015-07-17
CN110496122A (zh) 2019-11-26
JP2015525745A (ja) 2015-09-07
CA2877444A1 (en) 2014-01-03
CA2877444C (en) 2017-08-01
KR20140006233A (ko) 2014-01-16
PH12014502876B1 (en) 2015-02-23
ES2654207T3 (es) 2018-02-12
MY165075A (en) 2018-02-28
EP2868316A4 (en) 2016-02-17
SG11201408666SA (en) 2015-03-30
PE20150607A1 (es) 2015-05-16
PH12014502876A1 (en) 2015-02-23
JP6145506B2 (ja) 2017-06-14
BR112014032764A2 (pt) 2017-06-27
CN104602676A (zh) 2015-05-06
RU2015102553A (ru) 2016-08-20
CO7240413A2 (es) 2015-04-17
MX351521B (es) 2017-10-18
CL2014003525A1 (es) 2015-04-10
EP2868316B1 (en) 2017-12-06
WO2014003305A1 (ko) 2014-01-03
ZA201409508B (en) 2016-08-31
AU2013281582A1 (en) 2015-02-05
AU2013281582B2 (en) 2016-06-09
EP2868316A1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
KR20140006233A (ko) 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
RU2456989C2 (ru) Твердые лекарственные формы, содержащие тадалафил
TWI482641B (zh) 含有低取代度羥丙基纖維素之醫藥組成物
TWI325318B (en) Capsule and method of manufacturing the same
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
WO2008069262A1 (ja) 安定性が改善されたフィルムコーティング製剤
KR20180104125A (ko) 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물
EP3308774B1 (en) Hydroxyalkyl alkyl cellulose, method for producing the same, and solid preparation
JP2019065006A (ja) 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
CN113491695A (zh) 一种仑伐替尼药物组合物、其制备方法及应用
TWI586379B (zh) 一種製作難溶藥物固體劑型的方法
CN106511291A (zh) 一种盐酸阿考替胺缓释片剂及其制备方法
TWI720115B (zh) 一種含有喹啉衍生物或其鹽的醫藥組成物的製備方法
WO2021208976A1 (zh) 固体药物制剂及其制备方法和用途
TWI726978B (zh) 一種含有喹啉衍生物或其鹽的藥物組成物
EP2153822A1 (en) Granulation of active pharmaceutical ingredients
JPH02206A (ja) エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤
CN118986905B (zh) 一种甲磺酸阿帕替尼片及其制备方法
JP6112765B2 (ja) ロキソプロフェンナトリウム及びｄｌ−メチルエフェドリン塩酸塩を含有する固形製剤
JP2026506885A (ja) ミルベクシアン医薬組成物
BR112021004047A2 (pt) nova composição farmacêutica de lapatinib e processo para preparar uma nova composição farmacêutica de lapatinib
CN102614146A (zh) 制备非布索坦片的方法和非布索坦片

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170310

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180312

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190329

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 13